Charles M Baum is Founder, President, and CEO of Mirati Therapeutics, Inc.. Currently has a direct ownership of 0 shares of MRTX, which is worth approximately $0. The most recent transaction as insider was on Jan 23, 2024, when has been sold 237,871 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
100.0% 12M change
Total Value Held $0

CHARLES M BAUM Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 23 2024
SELL
Sale (or disposition) back to the issuer
-
237,871 Reduced 100.0%
0 Common Stock
Dec 29 2023
BUY
Grant, award, or other acquisition
$1,199,968 $58.75 p/Share
20,425 Added 7.62%
247,700 Common Stock
Aug 09 2023
BUY
Grant, award, or other acquisition
$1,999,998 $37.0 p/Share
54,054 Added 19.21%
227,275 Common Stock
Jan 20 2023
BUY
Grant, award, or other acquisition
-
4,444 Added 2.5%
173,221 Common Stock
Jan 04 2023
SELL
Open market or private sale
$169,996 $46.6 p/Share
3,648 Reduced 2.12%
168,777 Common Stock
Dec 21 2022
SELL
Open market or private sale
$367,498 $40.42 p/Share
9,092 Reduced 5.01%
172,425 Common Stock
Dec 19 2022
BUY
Grant, award, or other acquisition
-
53,618 Added 22.8%
181,517 Common Stock
Nov 28 2022
SELL
Open market or private sale
$6,925,600 $100.0 p/Share
69,256 Reduced 35.13%
127,899 Common Stock
Nov 28 2022
BUY
Exercise of conversion of derivative security
$1,205,746 $17.41 p/Share
69,256 Added 26.0%
197,155 Common Stock
Jan 18 2022
SELL
Open market or private sale
$303,248 $120.48 p/Share
2,517 Reduced 1.93%
127,899 Common Stock
Jan 18 2022
BUY
Exercise of conversion of derivative security
$99,981 $27.0 p/Share
3,703 Added 2.76%
130,416 Common Stock
Jan 14 2022
BUY
Grant, award, or other acquisition
-
25,543 Added 16.78%
126,713 Common Stock
Jan 04 2022
SELL
Open market or private sale
$610,559 $148.41 p/Share
4,114 Reduced 3.91%
101,170 Common Stock
Dec 16 2021
SELL
Bona fide gift
-
7,430 Reduced 6.59%
105,284 Common Stock
Dec 03 2021
SELL
Open market or private sale
$6,350,826 $134.54 p/Share
47,204 Reduced 29.52%
112,714 Common Stock
Dec 03 2021
BUY
Exercise of conversion of derivative security
$400,762 $8.49 p/Share
47,204 Added 22.79%
159,918 Common Stock
Jun 18 2021
SELL
Open market or private sale
$6,617,600 $165.44 p/Share
40,000 Reduced 26.19%
112,714 Common Stock
Jun 18 2021
BUY
Exercise of conversion of derivative security
$339,600 $8.49 p/Share
40,000 Added 20.76%
152,714 Common Stock
Jan 26 2021
BUY
Exercise of conversion of derivative security
$12,377 $5.4 p/Share
2,292 Added 1.99%
112,714 Common Stock
Jan 19 2021
BUY
Exercise of conversion of derivative security
$87,615 $27.0 p/Share
3,245 Added 2.85%
110,422 Common Stock
Jan 15 2021
BUY
Grant, award, or other acquisition
-
19,665 Added 15.5%
107,177 Common Stock
Jan 06 2021
SELL
Open market or private sale
$960,933 $213.02 p/Share
4,511 Reduced 4.9%
87,512 Common Stock
Dec 29 2020
SELL
Bona fide gift
-
10,000 Reduced 9.8%
92,023 Common Stock
Dec 18 2020
SELL
Open market or private sale
$9,458,800 $236.47 p/Share
40,000 Reduced 28.16%
102,023 Common Stock
Dec 18 2020
BUY
Exercise of conversion of derivative security
$339,600 $8.49 p/Share
40,000 Added 21.98%
142,023 Common Stock

Also insider at

IMMU
IMMUNOMEDICS INC
PMVP
PMV Pharmaceuticals, Inc. Healthcare
PSTX
Poseida Therapeutics, Inc. Healthcare
ACRV
Acrivon Therapeutics, Inc.
CMB

Charles M Baum

Founder, President, and CEO
San Diego, CA

Track Institutional and Insider Activities on MRTX

Follow Mirati Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MRTX shares.

Notify only if

Insider Trading

Get notified when an Mirati Therapeutics, Inc. insider buys or sells MRTX shares.

Notify only if

News

Receive news related to Mirati Therapeutics, Inc.

Track Activities on MRTX